Copyright
©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Apr 7, 2020; 26(13): 1513-1524
Published online Apr 7, 2020. doi: 10.3748/wjg.v26.i13.1513
Published online Apr 7, 2020. doi: 10.3748/wjg.v26.i13.1513
Evaluation of 177Lu-Dotatate treatment in patients with metastatic neuroendocrine tumors and prognostic factors
Estephany Abou Jokh Casas, Virginia Pubul Núñez, María del Carmen Mallón Araujo, Maria del Carmen Pombo Pasín, Miguel Garrido Pumar, Álvaro Ruibal Morell, Department of Nuclear Medicine, Santiago de Compostela´s University Hospital, Santiago de Compostela 15706, A Coruña, Spain
Urbano Anido-Herranz, Department of Oncology, Santiago de Compostela´s University Hospital, Santiago de Compostela 15706, A Coruña, Spain
José Manuel Cabezas Agrícola, Department of Endocrinology, Santiago de Compostela´s University Hospital, Santiago de Compostela, 15706, A Coruña, Spain
José Manuel Cameselle-Teijeiro, Department of Pathology, Santiago de Compostela´s University Hospital, Santiago de Compostela 15706, A Coruña, Spain
Ashraf Hilal, Department of Statistics, University of Santiago de Compostela, Santiago de Compostela 15706, A Coruña, Spain
Author contributions: Abou Jokh Casas E, Pubul Núñez V, del Carmen Mallón Araujo M and del Carmen Pombo Pasín M designed the research and wrote the paper; Anido-Herranz U, Hilal A and Garrido Pumar M contributed new reagents/analytic tools; Cabezas Agrícola JM, Cameselle-Teijeiro JM and Ruibal Morell Á analyzed the data.
Institutional review board statement: The study was reviewed and approved by the ethics committee.
Informed consent statement: All study participants, or their legal guardian, provided informed written consent prior to study enrollment.
Conflict-of-interest statement: There are no conflicts of interest to report.
Data sharing statement: No additional data are available.
STROBE statement: The authors have read the STROBE Statement-checklist of items, and the manuscript was prepared and revised according to the STROBE Statement-checklist of items.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Corresponding author: Estephany Abou Jokh Casas, MD, Occupational Physician, Department of Nuclear Medicine, Santiago de Compostela´s University Hospital, Avenida Choupana, Santiago de Compostela 15706, A Coruña, Spain. estephanyaboujokh@gmail.com
Received: December 8, 2019
Peer-review started: December 8, 2019
First decision: January 9, 2020
Revised: March 6, 2020
Accepted: March 19, 2020
Article in press: March 19, 2020
Published online: April 7, 2020
Processing time: 120 Days and 22.4 Hours
Peer-review started: December 8, 2019
First decision: January 9, 2020
Revised: March 6, 2020
Accepted: March 19, 2020
Article in press: March 19, 2020
Published online: April 7, 2020
Processing time: 120 Days and 22.4 Hours
Core Tip
Core tip: Peptide receptor radionuclide therapy has been used successfully in patients diagnosed with metastatic gastroenteropancreatic somatostatin receptor positive tumors when cytoreductive options are limited. In this study we found that overall survival was inversely proportional to toxicity to previous treatments, tumor grade, bone metastasis and directly proportional to matching lesion findings between Octreoscan and computed tomography pre-peptide receptor radionuclide therapy and primary tumor and metastasis surgery. Also, pseudo-progression in the middle of the treatment was a common finding that should be taken into consideration by clinicians in daily practice.